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Abstract. The performance of two histidine-rich protein type-2–based malaria rapid diagnostic tests (mRDTs) was
examined in a rural area with a high prevalence of malaria and human immunodeficiency virus type-1 (HIV-1) infection
in 113 and 445 febrile patients   15 years of age with and without HIV-1 infection, respectively. Patients were tested for
HIV-1 infection by using a standard assay and for Plasmodium falciparum by using two mRDTs and microscopy. When
microscopy was used as the gold standard, both mRDTs performed similarly in patients with and without HIV-1 infec-
tion: Bioline SD Malaria Antigen P.f, sensitivity 94.4% (95% confidence interval [CI]: 81.3–99.3%) versus 97.1% (95%
CI: 92.8–99.2%) and specificity 50.6% (95% CI: 39.0–62.2%) versus 47.2% (95% CI: 41.4–53.1%); and ICT diagnostics
Malaria Pf, sensitivity 94.4% (95% CI: 81.3–99.3%) versus 97.1% (95% CI: 92.8–99.2%) and specificity 50.6% (95%
CI: 39.0–62.2%) versus 50.3% (95% CI: 44.4–56.1%). Infection with HIV-1 does not appear to affect the performance of
these histidine-rich protein type-2 (HRP-2)-based mRDTs.
Malaria and human immunodeficiency virus (HIV) are
among the most important health problems in sub-Saharan
Africa. Malaria accounted for 781,000 deaths in 2009, of which
more than 80% occurred in sub-Saharan Africa.
1 In addition,
approximately 22.5 million adults and children in sub-Saharan
Africa have HIV infection and an estimated 1.3 million deaths
in the region were caused by acquired immunodeficiency
syndrome (AIDS) in 2009.
2 There is increasing evidence of an
interaction between malaria and HIV-1, and the impact of
co-infection is most apparent in areas with generalized HIV-1
epidemics and stable malaria transmission.
3–8 In Malawi, more
than 90% of the population is exposed to year-long, intense
malaria transmission and HIV-1 prevalence in adults is esti-
m a t e dt ob e1 2 % .
9 In adults, HIV-1 infection is associated
with increased episodes of uncomplicated malaria and
patients with low CD4 cell counts are particularly vulnerable
to malaria.
5,8,10,11
Resistance to first-line malaria treatments in sub-Saharan
Africa has made national malaria control programs switch
to more expensive but effective artemisinin combination
therapy.
12 This change in treatment policy, renewed calls for
malaria elimination, the need for reporting accurate sur-
veillance data, and innovations in malaria antigen detection
formats have contributed to revised recommendations for
obtaining an accurate diagnosis on the basis of parasitologic
confirmation before administering treatment. Currently, the
World Health Organization recommends that malaria case
management should be based on parasitologically confirmed
diagnosis in all cases. Given their relative ease of use, mRDTs
form a vital part of this strategy.
13
Infection with HIV-1 in adults is associated with high-
density parasitemia,
14 and performance of mRDTs is affected
by parasitemia density and the amount of circulating antigene-
mia.
15,16 HIV-positive adults are more likely to have fever than
HIV-negative adults, and acceptable mRDT performance is
critical for diagnosis of malaria and to rule out malaria as a
cause of fever.
17 The World Health Organization has set the
assessment of how malaria/HIV co-morbidity affects mRDT
results as one of the priority areas for operational research.
18
In this study, we assessed the sensitivity and specificity of
two commercially available histidine-rich protein type-2
(HRP-2)–based mRDTs in patients   15 years of age with and
without HIV-1 infection who came to a rural health center
with an acute febrile episode.
In a cross-section study design, patients were enrolled in
March–April 2009 at the outpatient department of Lirangwe
Health Center, a rural facility in the Blantyre District of
Malawi where there is year-round malaria transmission that
peaks during November–April. Patients with fever or a history
of fever within 48 hours and   15 years of age were eligible for
enrollment. Pregnant women and ill patients were excluded
from the study.
Eligible patients who provided informed consent or assent
(if < 18 years of age) were tested for HIV-1 by using Unigold
(catalog no. 1206502; Trinity Biotech Plc., Bray, Ireland) and
for malaria by using SD Bioline Malaria Antigen Pf (catalog
no. 05FK50, Standard Diagnostics, Seoul, South Korea), ICT
Malaria Pf Cassette Test (ICT Diagnostics, Cape Town, South
Africa) and a thick blood smear examination by light micros-
copy. Blood collected by a finger prick by trained community
health workers was used to prepare thick blood smears. The
blood smears were then sent to a College of Medicine laboratory
to be stained with Field’s Stains A and B (azure dye and eosin)
and read independently by two expert microscopists. Discordant
readings were resolved by a third microscopist.
A thick smear was considered positive if one or more
malaria parasite was visualized and considered negative if no
trophozoites were seen after examining 100 high-power fields
(100 +objective). The microscopistsw e r eb l i n d e dt oe a c ho t h e r ,
mRDT and HIV test results. Both mRDTs were conducted
by the same trained health workers according to the manu-
facturer’s instructions. The HIV-1 tests were performed in
the facility Voluntary, Counseling, and Testing room by
a ministry of health–certified counselor who was blinded to
mRDT results. Treatment of malaria was according to
mRDT results. Sensitivity, specificity, positive and neg-
ative predictive values of mRDTs in HIV-positive and HIV-
negative patients was assessed by using microscopy as the
gold standard.
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Chicago, IL) and analysis was performed by using STATA
version 10 (StataCorp, College Station, TX). Statistical testing
was done by using Pearson’s chi-square test or t-test, as appro-
priate. Agreement between the two mRDTs was measured by
using the kappa statistic. Significance was defined as P < 0.05.
The study protocol was approved by the Institutional Review
Board at the University of Malawi, College of Medicine.
A total of 650 eligible adult patients were invited to par-
ticipate in the study and 598 (92.0%) provided informed con-
sent and were enrolled. We included 558 (93.3%) patients with
available HIV test results in the analysis. Of these patients,
113 (20.2%) were HIV positive (Table 1). The prevalence of
Plasmodium falciparum parasitemia was 31.8% and 31.6%
in HIV-positive and HIV-negative patients, respectively. The
proportion of febrile patients (temperature   37.5 C) who
were parasitemic in HIV-positive and HIV-negative groups
was 40.0% and 46.7% respectively, but this difference was not
statistically significant (P ¼ 0.39). HIV-positive patients were
more likely to be older than HIV-negative patients (P < 0.01).
Only 36 (6.4%) of the 558 patients were co-infected
with HIV-1 and P. falciparum. Among these patients, 34 had
true-positive results (microscopy positive, RDT positive) for
both RDTs. Two patients had false negative results (micros-
copy positive but RDT negative) for both RDTs. The para-
site counts for the two patients were 780 parasites/mL and
2,210 parasites/mL, respectively.
Conversely, in the HIV-negative group, 137 patients had
true positive results for both RDTs and 4 patients had
false negative results and parasite counts of 10, 60, 200, and
590 parasites/mL. For HIV-negative patients with false posi-
tive results (microscopy negative but RDT positive), results of
the Bioline SD Malaria Antigen P.f and ICT Diagnostics
Malaria Pf were positive for 155 and 146 patients, respec-
tively. Both RDTs showed positive results for 145 patients.
The level of agreement between the two mRDTs was 98%
(kappa ¼ 0.96, P < 0.001).
There was no significant difference in the sensitivity, spec-
ificity, positive and negative predictive value of either Bioline
SD Malaria Antigen P.f or ICT Diagnostics Malaria Pf
Cassette Test for detecting P. falciparum asexual parasitemia
in HIV-positive versus HIV-negative patients (Table 2).
Although sensitivity was adequate (> 90%) for both mRDTs
regardless of HIV status, specificity was low for both mRDTs
(47.2–50.6%) regardless of HIV status.
We evaluated the accuracy of two HRP-2-based mRDTs
in HIV-positive and HIV-negative patients with acute febrile
illness seeking care at a rural health facility. The sensitivity
of both mRDTs was adequate (> 90%) in HIV-positive and
HIV-negative patients. Given that HIV-associated immuno-
suppression increases malaria incidence in HIV-positive
patients
5,8,10,11 and that HIV positive status is associated with
risk of getting an incorrect presumptive malaria diagnosis,
19
our finding are reassuring because most HIV-positive patients
with P. falciparum malaria would be appropriately diag-
nosed by using these HRP-2-based mRDTs. Only one study
has assessed performance of mRDTs in febrile HIV-positive
adults in sub-Saharan Africa. Using the Binax Now
W Malaria
Test (Inverness Medical Innovations Inc., Waltham, MA),
Mills and others reported comparable sensitivity (85.7%;
95% confidence interval: 57.2–98.2%) but high specificity
(97.8%; 95% confidence interval: 94.9–99.3%) for detection
of P. falciparum compared with a thick blood smear.
20
Both mRDTs evaluated in this study had low specificity in
HIV-positive and HIV-negative patients. Previous studies in
Malawi
21 and elsewhere
22,23 have also reported low specificity
TABLE 1
Demographic, clinical and laboratory characteristics of HIV-positive and HIV-negative patients   15 years of age with an acute febrile episode,
Lirangwe Health Center, Blantyre, Malawi, 2009
Characteristic HIV-positive (n ¼ 113) HIV-negative (n ¼ 445) P*
Age in years (mean) 32.2 26.8 0.01{
Weight in kilograms (mean) 48.5 45.5 0.01{
Female (%) 69.7 60.3 0.07
P. falciparum asexual parasitemia count (mean){ 2,542.2 3,848.0 0.24{
P. falciparum asexual parasitemia prevalence (%) 31.8 32.3 0.92
Febrile patients, temperature   37.5 C (%) 47.1 45.2 0.71
Febrile patients with parasitemia (%) 40.0 46.7 0.39
Used any mosquito net previous night (%) 89.2 83.9 0.29
Self-treated with antimalarial drugs before visit (%) 04.7 04.3 0.87
*By Pearson x
2 test unless otherwise noted.
{By Student’s t-test.
{n ¼ 36 for HIV-positive patients and n ¼ 141 for HIV negative patients. Mean parasitemia count is per microliter.
HIV ¼ human immunodeficiency virus.
TABLE 2
Performance of malaria rapid diagnostic tests compared with microscopy in HIV-positive and HIV-negative patients   15 years with an acute febrile
episode, Lirangwe Health Center, Blantyre, Malawi, 2009
Characteristic
SD Bioline malaria antigen Pf ICT Dagnostics Malaria Pf Cassette Test
HIV positive, n/N (%, 95% CI*) HIV negative, n/N (%, 95% CI*) P{ HIV positive, n/N (%, 95% CI*) HIV negative, n/N (%, 95% CI*) P{
Sensitivity 34/36 (94.4, 81.3–99.3) 137/141 (97.1, 92.8–99.2) 0.4 34/36 (94.4, 81.3–99.3) 137/141 (97.1, 92.8–99.2) 0.4
Specificity 39/77 (50.6, 39.0–62.2) 139/294 (47.2, 41.4–53.1) 0.6 39/77 (50.6, 39.0–62.2) 148/294 (50.3, 44.4–56.1) 0.9
Positive predictive value 34/72 (47.2, 35.3–59.3) 137/292 (46.9, 41.0–52.8) 0.9 34/72 (47.2, 35.3–59.3) 137/283 (48.4, 42.4–54.3) 0.8
Negative predictive value 39/41 (95.1, 83.4–99.4) 139/143 (97.2, 92.9–99.2) 0.5 39/41 (95.1, 83.4–99.4) 148/152 (97.3, 93.3–99.2) 0.4
*Binomial exact 95% confidence interval.
{By Pearson’s chi-square test.
HIV ¼ human immunodeficiency virus; PF ¼ Plasmodium falciparum.
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persistent circulating antigenemia after treatment with an
effective antimalarial drug, presence of sub-microscopic par-
asitemia, operator error in reading the mRDT test result
and other factors. Self-treatment with antimalarial drugs was
4.7% and 4.3% in the HIV-positive and HIV-negative groups,
respectively. Among these groups, 1 (20%) of 5 HIV-positive
patients had false positive results compared with 9 (48%) of
19 HIV-negative patients.
Although providing the correct diagnosis and treatment
of the true underlying cause of fever is critical in all febrile
patients, it is particularly important in HIV-positive patients
because they have multiple alternative causes for fever,
including opportunistic or other infections. A high rate of
false-positive results due to poorly specific mRDTs might lead
to over-treatment of malaria and under-treatment of other
causes of fever in this vulnerable population. However, it is
worth noting that consistent with findings of a large study of
mRDTs in areas with medium-to-high malaria transmission
rates in Uganda,
24 the negative predictive values of HRP-2-
based RDTs in this study and those in the study of Mills and
others
20 are high (> 95%). This finding implies that a negative
HRP-2-based RDT result can be an important point-of-care
tool for guiding clinicians to look for other causes of febrile
illness in HIV-positive patients.
In this study, malaria parasitemia prevalence among all
patients and parasite density among those infected with
malaria did not vary significantly between HIV-positive and
HIV-negative patients. These findings are similar to those of
a hospital-based study conducted in the region,
19 but incon-
sistent with results of another study, which reported substan-
tially higher malaria prevalence in HIV-positive patients than
in HIV-negative patients.
25 Similar levels of malaria in HIV-
positive and HIV-negative groups in our setting might be the
result of the fact that all patients in the study lived in an area
with similar malaria transmission intensity and had equal
access to malaria control interventions such as mosquito net
use (89.2% versus 83.9%; P ¼ 0.29) and malaria case manage-
ment. Because 98% of HIV-positive patients were diagnosed
for the first time in the study, it is also possible that HIV-
positive patients did not have substantial immunosuppres-
sion that might have made them more susceptible to malaria.
Lastly, the prevalence of HIV in patients attending the health
facility for an acute febrile illness episode (20.2%) was almost
twice the prevalence of HIV in the general population,
9 which
underscores the need for provider-initiated counseling and
testing for all adult patients with an acute febrile illness.
This study had several limitations. First, to estimate mRDT
sensitivity of 90   5%, with 80% power, we needed to enroll
138 HIV-positive parasitemic patients. However, we were
able to enroll only 36 HIV-positive parasitemic patients and
were thus underpowered.
26 Second, we were unable to mea-
sure CD4 cell counts in the HIV-positive patients and were
thus unable to assess the relationship between degree of
immunosuppression and mRDT test performance. Studies
on larger samples of adult patients with higher malaria/HIV
co-morbidity and that take into account CD4 cell counts are
needed to confirm these findings.
In summary, we found no difference in HRP-2-based mRDT
performance in HIV-positive and HIV-negative patients with
acute febrile illness in an area of high HIV and malaria preva-
lence. Clinicians in areas with high HIV and malaria preva-
lence should be vigilant for possible co-infection and should
use laboratory-based diagnostic tools for both diseases to
guide clinical management.
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